The Business Advisory Board is composed of leaders in the life-sciences and finance world with experience in the pharmaceutical, biotechnology, medical device, investment banking, venture capital and financial management industries. The BAB members assess grant and investment opportunities and provide advice and direction to support the commercialization of new therapies. The BAB members also work with the SAB and the Board in setting strategic direction to guide the organization and our programs.

• Stephen D. Collins, M.D., Ph.D.:  Co-Chair, Business Advisory Board
  President & CEO, NeuroTherapeutics Pharma, Inc.
• Garry E. Menzel, Ph.D.: Co-Chair, Business Advisory Board
  Executive Vice President Corporate Development and Finance, Regulus Therapeutics
  

  ---

• Karen L. Bergman
  Founder and Principal, BCC Partners
• Thomas A. Bologna
  President & Chief Executive Officer, Orchid Cellmark, Inc.
• Frank Fischer
  President & CEO, NeuroPace, Inc.
• Jeffrey D. Glidden
  Vice President & CFO, Airvana, Inc.
• Warren Lammert
  Founder, Managing Partner Granite Point Capital
• Heath Lukatch
  Partner, Novo Ventures
• Kevin Malone
  President and Founder, Greenrock Research
• Daniel J. O'Connell
  Director, NeuroVentures Capital LLC
• David A. Sadock
  President & CEO, Ethos Health Communications
• Nancy Santilli, B.S., M.S.N.
  VP Commercial Strategy and Portfolio Planning, Endo Pharmaceuticals, Inc.
• Ned Scheetz
  Managing Director, Aphelion Capital, LLC
• Lauren Silverman, Ph.D. 
  Managing Director, Novartis Option Fund                                                                                       
• Reese S. Terry, Jr.
  Founder, Cyberonics, Inc.
• Gregory T. Went, Ph.D.
  CEO & Chairman, NeuroMolecular Pharmaceuticals, Inc.
• Joyce A. Cramer (ex officio), President, Epilepsy Therapy Project and Associate Research Scientist, Yale University School of Medicine